Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 3.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 613,633 shares of the biopharmaceutical company's stock after purchasing an additional 19,112 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.66% of Ultragenyx Pharmaceutical worth $25,816,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Algert Global LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 46.9% during the 3rd quarter. Algert Global LLC now owns 73,902 shares of the biopharmaceutical company's stock worth $4,105,000 after acquiring an additional 23,580 shares during the last quarter. Bamco Inc. NY purchased a new stake in shares of Ultragenyx Pharmaceutical during the third quarter valued at $2,666,000. Principal Financial Group Inc. boosted its stake in shares of Ultragenyx Pharmaceutical by 740.0% during the third quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company's stock valued at $4,802,000 after purchasing an additional 76,150 shares during the period. Cerity Partners LLC bought a new position in shares of Ultragenyx Pharmaceutical in the third quarter worth about $1,773,000. Finally, Wealth Enhancement Advisory Services LLC increased its stake in Ultragenyx Pharmaceutical by 1.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 22,047 shares of the biopharmaceutical company's stock worth $928,000 after buying an additional 294 shares during the period. Institutional investors own 97.67% of the company's stock.

Remove Ads

Insider Activity

In other news, CFO Howard Horn sold 1,785 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $40.40, for a total transaction of $72,114.00. Following the transaction, the chief financial officer now owns 106,169 shares in the company, valued at $4,289,227.60. This trade represents a 1.65 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Theodore Alan Huizenga sold 967 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $40,710.70. Following the completion of the sale, the chief accounting officer now directly owns 50,265 shares of the company's stock, valued at approximately $2,116,156.50. The trade was a 1.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 136,370 shares of company stock worth $5,751,499 in the last ninety days. Company insiders own 5.80% of the company's stock.

Ultragenyx Pharmaceutical Stock Up 0.8 %

Shares of RARE stock traded up $0.31 on Friday, hitting $39.20. The company had a trading volume of 382,160 shares, compared to its average volume of 773,643. Ultragenyx Pharmaceutical Inc. has a twelve month low of $35.16 and a twelve month high of $60.37. The firm has a market cap of $3.63 billion, a P/E ratio of -6.18 and a beta of 0.67. The company has a 50-day moving average price of $41.94 and a 200-day moving average price of $47.62.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The company had revenue of $164.88 million during the quarter, compared to analysts' expectations of $163.23 million. Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. Equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on RARE. Wells Fargo & Company lifted their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a research report on Friday, December 20th. JPMorgan Chase & Co. dropped their price objective on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an "overweight" rating on the stock in a research report on Thursday, November 21st. Canaccord Genuity Group boosted their target price on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a report on Tuesday, February 18th. Piper Sandler reduced their price objective on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating for the company in a research note on Monday. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $91.71.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.